Shelke V - Search Results

1

ULK1 as a therapeutic target in kidney diseases: Current perspective.

Shreya S, Dagar N, Shelke V, Puri B, Gaikwad AB. Shreya S, et al. Among authors: shelke v. Expert Opin Ther Targets. 2024 Oct;28(10):911-922. doi: 10.1080/14728222.2024.2421762. Epub 2024 Nov 11. Expert Opin Ther Targets. 2024. PMID: 39526701 Review.

2

Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease.

Saxena S, Dagar N, Shelke V, Lech M, Khare P, Gaikwad AB. Saxena S, et al. Among authors: shelke v. Drug Discov Today. 2023 Nov;28(11):103765. doi: 10.1016/j.drudis.2023.103765. Epub 2023 Sep 9. Drug Discov Today. 2023. PMID: 37690600 Review.

3

Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management.

Saxena S, Dagar N, Shelke V, Puri B, Gaikwad AB. Saxena S, et al. Among authors: shelke v. Fundam Clin Pharmacol. 2024 Dec;38(6):1020-1030. doi: 10.1111/fcp.13031. Epub 2024 Aug 5. Fundam Clin Pharmacol. 2024. PMID: 39102849 Review.

4

Acyl-CoA Synthetase Long-Chain Isoenzymes in Kidney Diseases: Mechanistic Insights and Therapeutic Implications.

Mishra S, Shelke V, Gaikwad AB. Mishra S, et al. Among authors: shelke v. Cell Biochem Funct. 2024 Sep;42(7):e4114. doi: 10.1002/cbf.4114. Cell Biochem Funct. 2024. PMID: 39210707 Review.

5

Apelinergic system in acute kidney injury: Mechanistic insights and therapeutic potential.

Patil NS, Shelke V, Gaikwad AB. Patil NS, et al. Among authors: shelke v. Life Sci. 2024 Nov 1;356:123032. doi: 10.1016/j.lfs.2024.123032. Epub 2024 Aug 31. Life Sci. 2024. PMID: 39217720 Review.

6

Management of inflammaging in kidney diseases: focusing on the current investigational drugs.

Shelke V, Dagar N, Lech M, Gaikwad AB. Shelke V, et al. Expert Opin Investig Drugs. 2024 Nov;33(11):1153-1166. doi: 10.1080/13543784.2024.2417755. Epub 2024 Oct 16. Expert Opin Investig Drugs. 2024. PMID: 39403841 Review.

7

Long non-coding RNAs as emerging regulators of miRNAs and epigenetics in diabetes-related chronic kidney disease.

Shelke V, Kale A, Sankrityayan H, Anders HJ, Gaikwad AB. Shelke V, et al. Arch Physiol Biochem. 2024 Apr;130(2):230-241. doi: 10.1080/13813455.2021.2023580. Epub 2022 Jan 5. Arch Physiol Biochem. 2024. PMID: 34986074 Review.

8

Epigenetic regulation of Toll-like receptors 2 and 4 in kidney disease.

Shelke V, Kale A, Anders HJ, Gaikwad AB. Shelke V, et al. J Mol Med (Berl). 2022 Jul;100(7):1017-1026. doi: 10.1007/s00109-022-02218-y. Epub 2022 Jun 15. J Mol Med (Berl). 2022. PMID: 35704060 Review.

9

Cyproheptadine, a SET7/9 inhibitor, reduces hyperglycaemia-induced ER stress alleviating inflammation and fibrosis in renal tubular epithelial cells.

Sankrityayan H, Kale A, Shelke V, Gaikwad AB. Sankrityayan H, et al. Among authors: shelke v. Arch Physiol Biochem. 2024 Aug;130(4):411-419. doi: 10.1080/13813455.2022.2105365. Epub 2022 Aug 1. Arch Physiol Biochem. 2024. PMID: 35913792

10

Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity.

Kale A, Shelke V, Sankrityayan H, Dagar N, Gaikwad AB. Kale A, et al. Among authors: shelke v. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166532. doi: 10.1016/j.bbadis.2022.166532. Epub 2022 Aug 28. Biochim Biophys Acta Mol Basis Dis. 2022. PMID: 36041714 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters